Vectus BiosystemsASX:VBS 18 Quick Ratio is 0.58 as of Dec. 2025, which is 67% below its 10-year median of 1.75. GuruFocus rates ASX:VBS with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Vectus Biosystems ranks worse than 88.14% on this metric.
Vectus Biosystems has a quick ratio of 0.58. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Vectus Biosystems's Quick Ratio or its related term are showing as below:
ASX:VBS'
s Quick Ratio Range Over the Past 10 Years
Min: 0.06 Med: 1.75 Max: 5.99
Current: 0.58
During the past 10 years, Vectus Biosystems's highest Quick Ratio was 5.99. The lowest was 0.06. And the median was 1.75.
ASX:VBS's Quick Ratio is ranked worse than 88.14% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ASX:VBS: 0.58
Vectus Biosystems (ASX:VBS) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vectus Biosystems Quick Ratio Related Terms
Vectus Biosystems Quick Ratio Historical Data
* Premium members only.
The historical data trend for Vectus Biosystems's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:VBS vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Vectus Biosystems's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectus Biosystems Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectus Biosystems's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vectus Biosystems's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vectus Biosystems's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectus Biosystems (ASX:VBS) has a Quick Ratio of 0.58 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vectus Biosystems and its competitors. This is 67% below median its historical median of 1.75. Over the past decade, Vectus Biosystems' Quick Ratio has ranged from 0.06 to 5.99. According to the industry distribution chart, Vectus Biosystems ranks #1248 out of 1416 companies in the Biotechnology industry, placing it in the top 88.1%.
Is Vectus Biosystems' Quick Ratio too high?
Vectus Biosystems' current Quick Ratio of 0.58 is 67% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 5.99. The Biotechnology industry median Quick Ratio is 3.60. Vectus Biosystems' value of 0.58 is 83.9% below this industry median. Based on the distribution chart, Vectus Biosystems ranks #1248 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vectus Biosystems has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectus Biosystems ranks #1248 out of 1416 companies for Quick Ratio. This places Vectus Biosystems in the lower half of its industry. The industry median Quick Ratio is 3.60. Vectus Biosystems' value of 0.58 is 83.9% below this benchmark. Historically, Vectus Biosystems' own Quick Ratio has ranged from 0.06 to 5.99 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 3.60, Vectus Biosystems has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vectus Biosystems's current Quick Ratio of 0.58 is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vectus Biosystems and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectus Biosystems's current Quick Ratio is 0.58, which is 67% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current Quick Ratio of 0.58. The current Quick Ratio is 0.58, which is 67% below median its 10-year median of 1.75 and 83.9% below the Biotechnology industry median of 3.60. Vectus Biosystems' overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current Quick Ratio is 0.58 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
18GF Score
Get the complete analysis for ASX:VBS
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VBS has been successfully added to your 
